Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.
The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Yesterday, ExpreS2ion Biotechnologies' management presented the financial results for Q2 2026, provided further insights into the recent pipeline developments with focus on the breast cancer candidate. The session was followed by an Q&A
ExpreS2ion is expected to release its H1 2026 interim report on 20 August 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
I dag afholder vi fire online investorevents. Kl. 10:00 præsenterer ExpreS2ion Biotech CEO Bent U. Frandsen og CFO Keith Alexander halvårsrapporten for H1 2026. Kl. 11:00 gennemgår GrønlandsBANKEN bankdirektør Martin Kviesgaard regnskabet for 2. kvartal 2026. Kl. 12:30 præsenterer DFDS CFO Karen Dyrskjøt Boesen regnskabet for 2. kvartal 2026. Kl. 14:00 præsenterer BioPorto CEO Carsten Buhl og CFO Klaus Juhl Wulff halvårsrapporten for H1 2026. Tilmeld dig og stil dine spørgsmål allerede nu.
ExpreS2ion has today announced the outcome of the third scheduled DSMB meeting in the Phase I trial of ES2B C001, alongside expanded preliminary immunogenicity and safety data.
In connection with the Q1 2026 report, we have updated our investment case.
Q1 2026 has moved ExpreS2ion meaningfully forward and further derisked the investment case, with continued positive ES2B-C001 read-outs, a redesigned and strengthened Phase I programme, and a completed rights issue potentially securing the company's path to the end-2026 Phase I read-out.
Today, ExpreS2ion Biotechnologies' management presented the financial results for Q1 2026, provided further insights into the recent pipeline developments with focus on the breast cancer, malaria and Nipah candidates, and shared the latest updates on the completed rights issue and the partnering outlook for ES2B-C001.
ExpreS2ion is expected to release its Q1 2026 interim report on 28 May 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Markederne lukkede i går aftes i nye rekordniveauer, men her til morgen peger futures ned efter nye angreb på Iran. Herhjemme fokus på børsnoteringen af Biomar og Q1 fra Per Aarsleff, Imperio og ExpreS2ion.
